Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia

T Kita, Y Nagano, M Yokode, K Ishii, N Kume, A Ooshima, H Yoshida, C Kawai, T Kita, Y Nagano, M Yokode, K Ishii, N Kume, A Ooshima, H Yoshida, C Kawai

Abstract

In this study, we questioned whether in vivo probucol could prevent the progression of atherosclerosis in homozygous Watanabe heritable hyperlipidemic (WHHL) rabbits, an animal model for familial hypercholesterolemia. At 2 months of age, eight WHHL rabbits were divided into two groups. Group A (n = 4) was fed standard rabbit chow for 6 months. Group B (n = 4) was fed standard rabbit chow containing 1% probucol for 6 months. At the end of the experiments, average plasma concentrations of cholesterol were 704 +/- 121 mg/dl in group A and 584 +/- 61 mg/dl in group B, respectively. The percentage of surface area of total thoracic aorta with visible plaques in group A versus group B was 54.2% +/- 18.8% versus 7.0% +/- 6.3%, respectively. What was noteworthy was that the percentage of plaque in the descending thoracic aorta was almost negligible (0.2% +/- 0.2%) in group B rabbits compared to that in group A rabbits (41.1% +/- 20.2%). Low density lipoproteins (LDL) isolated from WHHL rabbits under treatment with probucol (group B) were shown to be highly resistant to oxidative modification by cupric ion and to be minimally recognized by macrophages. On the contrary, LDL from group A rabbits incubated with cupric ion showed a 7.4-fold increase in peroxides (thiobarbituric acid-reactive substances) and a 4.3-fold increase in the synthesis of cholesteryl ester in macrophages compared to those of LDL from group B rabbits. Thus, probucol could definitely prevent the progression of atherosclerosis in homozygous WHHL rabbits in vivo by limiting oxidative LDL modification and foam cell transformation of macrophages.

References

    1. Proc Natl Acad Sci U S A. 1979 Jan;76(1):333-7
    1. J Biol Chem. 1951 Nov;193(1):265-75
    1. Am J Pathol. 1979 Nov;97(2):327-57
    1. Proc Natl Acad Sci U S A. 1980 Apr;77(4):2214-8
    1. Proc Natl Acad Sci U S A. 1982 Sep;79(18):5693-7
    1. Atherosclerosis. 1980 Jun;36(2):261-8
    1. Proc Natl Acad Sci U S A. 1981 Apr;78(4):2268-72
    1. S Afr Med J. 1982 Jul 3;62(1):7-11
    1. Proc Natl Acad Sci U S A. 1982 May;79(10):3305-9
    1. Proc Natl Acad Sci U S A. 1982 Jun;79(11):3623-7
    1. Proc Soc Exp Biol Med. 1971 Apr;136(4):1216-21
    1. J Am Geriatr Soc. 1974 Apr;22(4):167-75
    1. Arteriosclerosis. 1983 Jan-Feb;3(1):87-101
    1. N Engl J Med. 1983 Aug 4;309(5):288-96
    1. Arteriosclerosis. 1983 Jul-Aug;3(4):283-301
    1. Annu Rev Biochem. 1983;52:223-61
    1. Atherosclerosis. 1983 Aug;48(2):157-66
    1. J Chromatogr. 1983 Oct 14;277:419-22
    1. Proc Natl Acad Sci U S A. 1984 Jun;81(12):3883-7
    1. Arteriosclerosis. 1984 Jul-Aug;4(4):357-64
    1. J Clin Invest. 1984 Nov;74(5):1890-4
    1. N Engl J Med. 1984 Dec 27;311(26):1658-64
    1. J Am Coll Cardiol. 1985 Jul;6(1):141-4
    1. Atherosclerosis. 1985 Jul;56(1):71-9
    1. Arteriosclerosis. 1985 Nov-Dec;5(6):613-22
    1. J Clin Invest. 1986 Feb;77(2):641-4
    1. Atherosclerosis. 1986 Jan;59(1):47-56
    1. Science. 1986 Apr 4;232(4746):34-47
    1. J Clin Invest. 1986 May;77(5):1460-5
    1. Am J Cardiol. 1986 Jun 27;57(16):16H-21H
    1. Am J Cardiol. 1986 Jun 27;57(16):29H-35H
    1. Proc Natl Acad Sci U S A. 1987 Jan;84(2):537-40
    1. Atherosclerosis. 1986 Dec;62(3):209-17
    1. J Cell Biol. 1979 Sep;82(3):597-613

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe